一项接种一系列2 ﹢ 1剂CRM197﹣Hib疫苗或破伤风类毒素﹣Hib疫苗后IIIb期、对照、开放性、单中心、持久性、扩展试验
[Translation] A phase IIIb, controlled, open-label, single-center, persistent, extended-term trial of 2 + 1 doses of CRM197-Hib vaccine or tetanus toxoid-Hib vaccine
评价参加前一试验V37_07E1的儿童加强接种Hib﹣CRM197或Hib﹣TT后大约4年其抗﹣PRP抗体的持久性。
[Translation] To evaluate the persistence of anti-PRP antibodies approximately 4 years after booster vaccination with Hib-CRM197 or Hib-TT in children who participated in the previous trial, V37_07E1.
100 Clinical Results associated with Italy Novartis Vaccines and Diagnostics Co., Ltd. Beijing Representative Office
0 Patents (Medical) associated with Italy Novartis Vaccines and Diagnostics Co., Ltd. Beijing Representative Office
100 Deals associated with Italy Novartis Vaccines and Diagnostics Co., Ltd. Beijing Representative Office
100 Translational Medicine associated with Italy Novartis Vaccines and Diagnostics Co., Ltd. Beijing Representative Office